四環醫藥(00460.HK)旗下心衰藥取得藥品註冊證書
四環醫藥(00460.HK)公布,佛山德芮可製藥的琥珀酸美托洛爾緩釋片(47.5mg、95mg)於2021年9月取得中國國家藥品監督管理局藥品註冊證書,而集團擁有該產品在中國大陸地區之產品獨家市場推廣權。
美托洛爾是全球首個選擇性β1受體阻滯劑,可降低支氣管收縮風險,因而成為慢性心衰常用藥物。琥珀酸美托洛爾緩釋片為治療高血壓、心絞痛、慢性心衰竭、在心肌梗塞急性期後、預防心肌死亡及再梗塞、心律不整、有心悸症狀功能性心臟疾病等適應症的藥物。
四環醫藥控股集團主席兼執行董事車馮升稱,是次琥珀酸美托洛爾緩釋片取得藥品註冊證書,將有利於該藥品未來的市場銷售和市場競爭,將對集團的經營業績產生積極影響。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.